TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
STAMFORD, Conn., Nov. 15, 2016 -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced that new preclinical data for the company’s LOXO-292 and LOXO-195 programs will be presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics taking place November 29 – December 2, 2016 in Munich, Germany.
The details of the poster presentations are as follows:
LOXO-292
Date: December 1, 2016
Title: The development of a potent, KDR/VEGFR2-sparing RET kinase inhibitor for treating patients with RET-dependent cancers
Session: Molecular targeted agents II
Abstract Code: 441
Poster Number: 120
Location: Exhibition Hall
LOXO-195
Date: December 1, 2016
Title: The development of LOXO-195, a second generation TRK kinase inhibitor that overcomes acquired resistance to 1st generation inhibitors observed in patients with TRK-fusion cancers
Session: Molecular targeted agents II
Abstract Code: 442
Poster Number: 121
Location: Exhibition Hall
About Loxo Oncology
Loxo Oncology is a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers. Our pipeline focuses on cancers that are uniquely dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. We believe that the most selective, purpose-built medicines have the highest probability of maximally inhibiting the intended target, thereby delivering best-in-class disease control and safety. Our management team seeks out experienced industry partners, world-class scientific advisors and innovative clinical-regulatory approaches to deliver new cancer therapies to patients as quickly and efficiently as possible. For more information, please visit the company's website at www.loxooncology.com.
Contacts for Loxo Oncology, Inc.
Company:
Jacob S. Van Naarden
Chief Business Officer
[email protected]
Investors:
Peter Rahmer
The Trout Group, LLC
646-378-2973
[email protected]
Media:
Dan Budwick
Pure Communications, Inc.
973-271-6085
[email protected]
